摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl (5-(4-methoxyphenyl)pentyl)carbamate | 905293-02-9

中文名称
——
中文别名
——
英文名称
tert-butyl (5-(4-methoxyphenyl)pentyl)carbamate
英文别名
tert-butyl N-[5-(4-methoxyphenyl)pentyl]carbamate
tert-butyl (5-(4-methoxyphenyl)pentyl)carbamate化学式
CAS
905293-02-9
化学式
C17H27NO3
mdl
——
分子量
293.406
InChiKey
QFEGRKFTTYHIGA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    21
  • 可旋转键数:
    9
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    47.6
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl (5-(4-methoxyphenyl)pentyl)carbamate三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 生成 5-(4-Methoxyphenyl)pentan-1-amine;2,2,2-trifluoroacetic acid
    参考文献:
    名称:
    Design, Synthesis, and Structure−Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers:  Drugs for Cystic Fibrosis and Chronic Bronchitis
    摘要:
    Amiloride (1), the prototypical epithelial sodium channel (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmonary function in patients with the genetic disorder cystic fibrosis. This study was conducted to synthesize and identify more potent, less reversible ENaC blockers, targeted for aerosol therapy and possessing minimal systemic renal activity. A series of novel 2-substituted acylguanidine analogues of amiloride were synthesized and evaluated for potency and reversibility on bronchial ENaC. All compounds tested were more potent and less reversible at blocking sodium-dependent shortcircuit current than amiloride. Compounds 30-34 showed the greatest potency on ENaC with IC50 values below 10 nM. A regioselective difference in potency was found (compounds 30, 39, and 40), whereas no stereospecific (compounds 33, 34) difference in potency on ENaC was displayed. Lead compound 32 was 102-fold more potent and 5-fold less reversible than amiloride and displayed the lowest IC50 value ever reported for an ENaC blocker.
    DOI:
    10.1021/jm051134w
  • 作为产物:
    描述:
    N-(4-戊炔基)氨基甲酸叔丁酯 在 palladium on activated charcoal 、 copper(l) iodide 氢气二乙胺三苯基膦 、 palladium dichloride 作用下, 以 乙醇 为溶剂, 20.0 ℃ 、344.74 kPa 条件下, 反应 24.0h, 生成 tert-butyl (5-(4-methoxyphenyl)pentyl)carbamate
    参考文献:
    名称:
    Design, Synthesis, and Structure−Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers:  Drugs for Cystic Fibrosis and Chronic Bronchitis
    摘要:
    Amiloride (1), the prototypical epithelial sodium channel (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmonary function in patients with the genetic disorder cystic fibrosis. This study was conducted to synthesize and identify more potent, less reversible ENaC blockers, targeted for aerosol therapy and possessing minimal systemic renal activity. A series of novel 2-substituted acylguanidine analogues of amiloride were synthesized and evaluated for potency and reversibility on bronchial ENaC. All compounds tested were more potent and less reversible at blocking sodium-dependent shortcircuit current than amiloride. Compounds 30-34 showed the greatest potency on ENaC with IC50 values below 10 nM. A regioselective difference in potency was found (compounds 30, 39, and 40), whereas no stereospecific (compounds 33, 34) difference in potency on ENaC was displayed. Lead compound 32 was 102-fold more potent and 5-fold less reversible than amiloride and displayed the lowest IC50 value ever reported for an ENaC blocker.
    DOI:
    10.1021/jm051134w
点击查看最新优质反应信息

文献信息

  • Heterocyclization involving benzylic C(sp<sup>3</sup>)–H functionalization enabled by visible light photoredox catalysis
    作者:Ganesh Pandey、Ramkrishna Laha、Pradip Kumar Mondal
    DOI:10.1039/c9cc04287c
    日期:——
    A general and efficient method for heterocyclization involving benzylic C(sp3)–H functionalization enabled by visible light photoredox catalysis to access a wide range of structurally diverse oxygen as well as nitrogen heterocycles up to a gram scale is reported. The potential application of this new methodology is demonstrated by the total synthesis of (−)-codonopsinine and (+)-centrolobine. Herein
    据报道,一种通用有效的杂环化方法涉及苄基C(sp 3)–H官能团,该官能团通过可见光光氧化还原催化作用可访问范围广泛的结构多样的氧和氮杂环,直至克级。(-)-codonopsinine和(+)-centrolobine的总合成证明了这种新方法的潜在应用。在本文中提出了与氟化试剂不同,selectfluor用作氧化猝灭剂和氢自由基受体。
  • Design, Synthesis, and Structure−Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers:  Drugs for Cystic Fibrosis and Chronic Bronchitis
    作者:Andrew J. Hirsh、Bruce F. Molino、Jianzhong Zhang、Nadezhda Astakhova、William B. Geiss、Bruce J. Sargent、Brian D. Swenson、Alexander Usyatinsky、Michael J. Wyle、Richard C. Boucher、Rick T. Smith、Andra Zamurs、M. Ross Johnson
    DOI:10.1021/jm051134w
    日期:2006.7.1
    Amiloride (1), the prototypical epithelial sodium channel (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmonary function in patients with the genetic disorder cystic fibrosis. This study was conducted to synthesize and identify more potent, less reversible ENaC blockers, targeted for aerosol therapy and possessing minimal systemic renal activity. A series of novel 2-substituted acylguanidine analogues of amiloride were synthesized and evaluated for potency and reversibility on bronchial ENaC. All compounds tested were more potent and less reversible at blocking sodium-dependent shortcircuit current than amiloride. Compounds 30-34 showed the greatest potency on ENaC with IC50 values below 10 nM. A regioselective difference in potency was found (compounds 30, 39, and 40), whereas no stereospecific (compounds 33, 34) difference in potency on ENaC was displayed. Lead compound 32 was 102-fold more potent and 5-fold less reversible than amiloride and displayed the lowest IC50 value ever reported for an ENaC blocker.
查看更多